Overcoming Resistance to Immunotherapy Combining Gemcitabine With Ivonescimab in Advanced NSCLC

This Phase II clinical trial (investigates the efficacy of combining gemcitabine, a chemotherapy agent, with ivonescimab, a bispecific PD-1/VEGF antibody, in patients with advanced non-small cell lung cancer (NSCLC) who have experienced disease progression following chemoimmunotherapy (CIT). Lung cancer remains the leading cause of cancer-related death globally, and treatment options after CIT failure are limited. Gemcitabine has demonstrated immunostimulatory properties, including enhanced T-cell infiltration and reduced immunosuppressive cell populations, which may synergize with immune chec

Trial Details

NCT ID
NCT07158489
Phase
PHASE2
Sponsor
Swiss Cancer Institute
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Gemcitabine + Ivonescimab
Locations (sample)
  • Baden, Switzerland|47.47333,8.30592
  • Basel, Switzerland|47.55839,7.57327
  • Bellinzona, Switzerland|46.19278,9.01703
  • Chur, Switzerland|46.84986,9.53287
  • Fribourg, Switzerland|46.80237,7.15128

Key Eligibility Criteria

  • Patients fulfilling all of the following inclusion criteria are eligible for the trial:
  • Written informed consent according to Swiss law and ICH GCP E6 regulations before registration and prior to any trial specific procedures including…
  • Confirmed squamous or non-squamous mNSCLC stage IIIB-IV (based on 9th edition Tumor-Node-Metastasis (TNM) classification of lung cancers with disea…
  • Patients with treated and stable central nervous system (CNS) metastases are eligible, if:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →